New Classifications for Myelodysplastic Syndromes (MDS)

Dr. Ellen Ritchie recently participated in an OncLive discussion on the latest modifications to the World Health Organization (WHO) classification of Myelodysplastic Syndromes (MDS). WHO classification is the standard diagnostic system utilized by medical institutions worldwide, including here at Weill Cornell Medicine. Recent advances in our understanding of the biological course of MDS have warranted revision to its WHO classification, which was last updated in 2008. In particular, mutational and cytogenetic analyses have to led to refinement of diagnostic terms for MDS. These modifications include a distinction between single versus multilineage dysplasia and elimination of the term “cytopenia.”

The OncLive discussion centered on implications of the new classification on the prognosis and treatment of MDS. While the WHO classification is just one of many factors to consider when evaluating the prognosis of the disorder, the panelists agree that the new modifications will make it easier to determine an appropriate course of treatment for their patients. To learn more, click here or watch the video below.


Cancer Care: The Next Generation

Dr. Gail Roboz on ABC talks about “taking a chance on something new.” [go]

 

 

 

 

 


Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL

This clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic & Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U). Click here to learn more or see if you are eligible to participate.


What to Expect When You’re Expecting MDS

Dr. Ritchie provides and in-depth look at what it takes to diagnose MDS. For more information visit crushdmds.org.


Dr. Desai – Treatment for Intermediate & High Risk MDS

Dr. Desai discusses approved treatments for intermediate and high risk MDS. For more information visit crushmds.org.


Six Top Medical Institutions Launch Research Alliance Program to ‘CRUSH MDS’, a Rare Form of Blood Cancer

Joint Effort Expands Experts’ Capacity to Develop Treatments, Find a Cure

crush_mds_logoEx-marine Kevin Chambers had always been a strong and powerfully built man. The retired 66-year-old Vietnam War veteran used to work as a professional bodyguard in New York City, providing personal security for major celebrities like Michael Jackson, James Cagney and Barbra Streisand. Last year, Chambers needed a wheelchair and a walker just to get around. 

“I got sick in 2014 and felt so strange and weak in so many ways,” said Chambers. After being initially diagnosed with severe anemia along with two other conditions, later test results showed he had atypical myelodysplastic syndrome (MDS), a life-threatening bone marrow failure disease. Thanks to his daughter, an editor at ABC’s Good Morning America, Chambers was referred to Dr. Gail Roboz, the specialist who treated the show’s co-anchor Robin Roberts for MDS.

Roboz is with the Weill Medical College of Cornell University, one of the six preeminent institutions that form the MDS Clinical Research Consortium (MDS CRC). The others include the Cleveland Clinic Taussig Cancer Institute, the Dana-Farber Cancer Center in Boston, MD Anderson Cancer Center in Houston, H. Lee Moffitt Cancer Center and Research Institute in Tampa, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore.

The MDS CRC was created with a grant from the Edward P. Evans Foundation. Suffering from MDS himself, philanthropist Evans was determined to speed up drug development by minimizing excessive “red tape” in clinical research. The CRC is the first collaboration of its kind, and its investigators lead unique, high-quality clinical and laboratory studies aimed at improving the lives of MDS patients. It recently launched a website with a public initiative called the Clinical Repository to Understand, Study and Heal Myelodysplastic Syndromes, otherwise known as CRUSH!!MDS.

The consortium works to accelerate and amplify the research conducted at these leading cancer centers. The beneficiaries are patients like Kevin Chambers, who Dr. Roboz quickly involved in a clinical trial. With careful monitoring of his blood cell counts and reactions to drugs, she was able to customize his care with precision treatments that were regularly adjusted based on his progress.

One year later, Chambers is walking again and his strength has vastly improved. He used to need a blood transfusion every two weeks. Now his transfusions are five weeks apart. He jokes that when he has enough blood, he doesn’t even need to nap. “I work very closely with Dr. Roboz and, if I don’t follow what she says, she kind of gives me hell by thanking me for my medical opinion.” That toughness combined with constant attention to the clinical data is how the specialists CRUSH MDS. For more information visit crushmds.org.

Press release originally posted on AAMDS March 2, 2016


AAMDS Patient Conferences 2016

Following are conferences conducted by AAMDS afford you the opportunity to meet top experts and fellow patients at a free program near you:

Living with Aplastic Anemia, MDS, and PNH

Washington, D.C.
Saturday, March 19, 2016
8:30a to 4:30p
For location and registration

Cincinnati, OH
Saturday, April 30, 2016
8:30a to 4:30p
For location and registration
*Interactive kids program – art activities to further their understanding, ice cream social

Raleigh, NC
Saturday, July 16, 2016
8:30a to 4:30p
For location and registration

San Diego, CA
Saturday, September 17, 2016
8:30a to 4:30p
For location and registration
*Disease track sessions will be offered in Spanish at this location. For more information and registration, please visit aamds.or/eventos

San Antonio, TX
Saturday, October 8, 2016
8:30a to 4:30p
For location and registration
*Disease track sessions will be offered in Spanish at this location. For more information and registration, please visit aamds.org/eventos

West Palm Beach, FL
Sunday, November 6, 2016
8:30a to 4:30p
For location and registration

Seattle, WA – Welcome to the 6th Biennial Conference on Marrow Failure
Saturday, June 18, 2016
8:30a to 4:30p
For location and registration
*Joint event with the Fred Hutchinson Cancer Research Institute

For questions and more information please visit the AAMDS conference page